Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/1797
Title: | Trends in intra-aortic balloon pump use in cardiogenic shock in the post-SHOCK II trial era. |
Author: | Nan, Tie E. Dinh, D. Clark, D. Ajani, A. Brennan, A. Cohen, N. Dagan, M. Shaw, J. Sebastian, M. Freeman, M. Oqueli, Ernesto Reid, C. Kaye, D. Stub, D. Duffy, S. |
Issue Date: | 2021 |
Conference Name: | 69th CSANZ Annual Scientific Meeting 43rd Annual Scientific Meeting of the International Society for Heart Research ANZET 21 |
Conference Date: | August 4-7 |
Conference Place: | Online |
Abstract: | Background: Myocardial infarction complicated by cardiogenic shock (MI-CS) has a poor prognosis, even with early revascularisation. Previously, intra-aortic balloon pump (IABP) use was thought to improve outcomes, but the SHOCK-II trial (Intraaortic Balloon Pump in Cardiogenic Shock II) found no survival benefit. Objective: This study determined the trends in IABP use in patients with MI-CS undergoing percutaneous intervention (PCI) over time. Methods: Between 2005 and 2018, patients presenting with MI-CS who underwent PCI at a hospital participating in the Melbourne Interventional Group Registry were included. Results: Of the 1,110 patients identified, IABP was used in 478 (43%). IABP was used more in patients with left main and LAD culprit lesions (62% vs 46%), lower ejection fraction (<35%: 18% vs 11%), and preprocedural inotrope use (81% vs 73%; all p<0.05). IABP use was associated with higher in-patient bleeding (18% vs 13%) and 30-day major adverse cardiovascular and cerebrovascular events (MACCE; 58% vs 51%; both p<0.05). The rate of MI-CS increased over time, but after 2012 there was a decline in IABP use (Figure 1). IABP use was a predictor of 30-day MACCE (odds ratio, 1.6; 95% confidence interval, 1.18–2.29 [p=0.003]). However, IABP was not associated with in-hospital, 30-day, or long-term mortality. Conclusion: Consistent with the SHOCK-II trial, IABP use does not reduce short- or long-term mortality, but in this study was associated with increased short-term adverse events. IABP use is declining but is still used in sicker patients with greater myocardium at risk, given limited alternatives. |
URI: | http://hdl.handle.net/11054/1797 |
Internal ID Number: | 01760 |
Health Subject: | CARDIOGENIC SHOCK CARDIOLOGY MYOCARDIAL INFARCTION INTRAAORTIC BALLOON PUMP |
Type: | Conference Paper |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.